Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-993X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment ; volume:22 ; number:1 ; day:1 ; month:4 ; year:2021 ; pages:1-9 ; date:12.2021
Respiratory research ; 22, Heft 1 (1.4.2021), 1-9, 12.2021
- Creator
-
Biondini, Davide
Cocconcelli, Elisabetta
Bernardinello, Nicol
Lorenzoni, Giulia
Rigobello, Chiara
Lococo, Sara
Castelli, Gioele
Baraldo, Simonetta
Cosio, Manuel G.
Gregori, Dario
Saetta, Marina
Balestro, Elisabetta
Spagnolo, Paolo
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12931-021-01694-z
- URN
-
urn:nbn:de:101:1-2021051721435505784272
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:52 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Biondini, Davide
- Cocconcelli, Elisabetta
- Bernardinello, Nicol
- Lorenzoni, Giulia
- Rigobello, Chiara
- Lococo, Sara
- Castelli, Gioele
- Baraldo, Simonetta
- Cosio, Manuel G.
- Gregori, Dario
- Saetta, Marina
- Balestro, Elisabetta
- Spagnolo, Paolo
- SpringerLink (Online service)
Other Objects (12)
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis
Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis
MiR-608 overexpression in idiopathic pulmonary fibrosis (IPF)
Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications
Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE
Clinical characteristics of patients with familial idiopathic pulmonary fibrosis (f-IPF)
Antifibrotic therapies to control cardiac fibrosis
Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients
Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry
Management and attitudes about IPF (Idiopathic Pulmonary Fibrosis) among physicians from Latin America
Pulmonary 18F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF)
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis
Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis
MiR-608 overexpression in idiopathic pulmonary fibrosis (IPF)
Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications
Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE
Clinical characteristics of patients with familial idiopathic pulmonary fibrosis (f-IPF)
Antifibrotic therapies to control cardiac fibrosis
Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients
Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry
Management and attitudes about IPF (Idiopathic Pulmonary Fibrosis) among physicians from Latin America
Pulmonary 18F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF)
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis
Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis
MiR-608 overexpression in idiopathic pulmonary fibrosis (IPF)
Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications
Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE
Clinical characteristics of patients with familial idiopathic pulmonary fibrosis (f-IPF)
Antifibrotic therapies to control cardiac fibrosis
Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients
Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry
Management and attitudes about IPF (Idiopathic Pulmonary Fibrosis) among physicians from Latin America